A Phase 1b Open Label Study Investigating the Safety and Efficacy of Blinatumomab in Combination With Pembrolizumab in Adult Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (KEYNOTE-348)
Not yet recruiting
Phase of Trial: Phase I
Latest Information Update: 21 Dec 2017
At a glance
- Drugs Blinatumomab (Primary) ; Pembrolizumab (Primary)
- Indications Diffuse large B cell lymphoma
- Focus Adverse reactions
- Acronyms KEYNOTE-348
- Sponsors Amgen
- 14 Dec 2017 Planned End Date changed from 4 Dec 2024 to 7 Jan 2025.
- 14 Dec 2017 Planned primary completion date changed from 17 Feb 2021 to 23 Mar 2021.
- 14 Dec 2017 Planned initiation date changed from 31 Jan 2018 to 2 Mar 2018.